UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Alopecia universalis occurring after alemtuzumab treatment for multiple sclerosis. A two-year follow-up of two patients

Borriello, G; Ianniello, A; Toosy, AT; (2021) Alopecia universalis occurring after alemtuzumab treatment for multiple sclerosis. A two-year follow-up of two patients. International Journal of Environmental Research and Public Health , 18 (14) , Article 7338. 10.3390/ijerph18147338. Green open access

[thumbnail of ijerph-18-07338.pdf]
Preview
Text
ijerph-18-07338.pdf - Published Version

Download (1MB) | Preview

Abstract

Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody used in the treatment of Multiple Sclerosis (MS), but it causes secondary autoimmunity in up to 40% of patients. Many factors are believed to contribute to this process, but pathogenic mechanisms are not well clear. To date, three cases of AU after treatment with Alemtuzumab have been reported. In this paper we report the cases of two patients who developed AU 12 months after the second cycle of Alemtuzumab, with a review of the literature. One year after the end of the second cycle, two female patients in their thirties experienced complete hair loss. The first case was temporally associated with a significant drop in vitamin D (VD) levels. The second case was accompanied by joint swelling. Both patients had thyroid alterations and showed no hair regrowth after a 2-year follow-up. AU must be considered among the secondary autoimmune manifestations of Alemtuzumab treatment. We emphasize the need for appropriate patient screening and thorough clinical surveillance for factors predisposing patients to secondary autoimmunity.

Type: Article
Title: Alopecia universalis occurring after alemtuzumab treatment for multiple sclerosis. A two-year follow-up of two patients
Open access status: An open access version is available from UCL Discovery
DOI: 10.3390/ijerph18147338
Publisher version: https://doi.org/10.3390/ijerph18147338
Language: English
Additional information: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10131862
Downloads since deposit
15Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item